Published in Cancer Res on October 01, 2003
Novel roles for α-crystallins in retinal function and disease. Prog Retin Eye Res (2012) 1.17
Heat shock protein 27: its potential role in vascular disease. Int J Exp Pathol (2006) 1.09
Statistical model to analyze quantitative proteomics data obtained by 18O/16O labeling and linear ion trap mass spectrometry: application to the study of vascular endothelial growth factor-induced angiogenesis in endothelial cells. Mol Cell Proteomics (2009) 1.06
HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol (2007) 1.05
Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res (2008) 1.04
Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res (2004) 0.92
Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Sci (2008) 0.87
Comprehensive characterization of heat shock protein 27 phosphorylation in human endothelial cells stimulated by the microbial dithiole thiolutin. J Proteome Res (2008) 0.85
Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma. PLoS One (2011) 0.84
Potential therapeutic implications of intracrine angiogenesis. Med Hypotheses (2007) 0.84
Differential heat shock protein localization in chronic lymphocytic leukemia. J Leukoc Biol (2009) 0.84
Thiolutin inhibits endothelial cell adhesion by perturbing Hsp27 interactions with components of the actin and intermediate filament cytoskeleton. Cell Stress Chaperones (2009) 0.83
Actin realignment and cofilin regulation are essential for barrier integrity during shear stress. J Cell Biochem (2013) 0.81
Protein expression profiling in the spectrum of renal cell carcinomas. J Cancer (2010) 0.81
A monoclonal rat anti-mouse EMAP II antibody that functionally neutralizes pro- and mature-EMAP II in vitro. J Immunol Methods (2009) 0.81
The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins. Invest New Drugs (2012) 0.80
Proteomic Analysis of Embryonic and Young Human Vitreous. Invest Ophthalmol Vis Sci (2015) 0.80
Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis. Circ Res (2016) 0.78
Increasing radiosensitivity with the downregulation of cofilin-1 in U251 human glioma cells. Mol Med Rep (2014) 0.78
Regulators of Actin Dynamics in Gastrointestinal Tract Tumors. Gastroenterol Res Pract (2015) 0.78
Release of membrane-bound vesicles and inhibition of tumor cell adhesion by the peptide Neopetrosiamide A. PLoS One (2010) 0.77
Distinct effects of contraction agonists on the phosphorylation state of cofilin in pulmonary artery smooth muscle. Adv Pharmacol Sci (2007) 0.75
Homocysteine inhibits angiogenesis through cytoskeleton remodeling. Biosci Rep (2017) 0.75
von Hippel-Lindau disease. Lancet (2003) 6.20
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem (2006) 2.23
Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A (2005) 2.17
Increasing survival of ischemic tissue by targeting CD47. Circ Res (2007) 2.16
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res (2010) 1.91
Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2008) 1.81
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood (2007) 1.73
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (2002) 1.65
Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab (2009) 1.62
Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood (2006) 1.56
Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A (2005) 1.55
OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol (2006) 1.53
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med (2007) 1.49
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med (2009) 1.47
Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int (2004) 1.44
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res (2006) 1.43
Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem (2007) 1.41
Arginine-induced germ tube formation in Candida albicans is essential for escape from murine macrophage line RAW 264.7. Infect Immun (2009) 1.38
Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques (2003) 1.36
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem (2008) 1.34
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One (2009) 1.33
The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal (2006) 1.32
Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res (2003) 1.32
Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+ -sensing receptor. Mol Endocrinol (2006) 1.31
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging (2002) 1.30
Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging (2003) 1.30
Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res (2008) 1.30
Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol (2002) 1.29
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res (2008) 1.29
Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res (2007) 1.28
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem (2010) 1.27
CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy (2012) 1.27
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol (2008) 1.26
Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A (2007) 1.26
Successful outcome after surgical management in two cases of the "painful variant" of Hashimoto's thyroiditis. Endocr Pract (2002) 1.25
Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol (2007) 1.25
Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer (2009) 1.25
Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy. Cell Biosci (2014) 1.24
Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg (2008) 1.24
Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol (2009) 1.23
Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem (2006) 1.22
Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene (2004) 1.22
Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res (2004) 1.21
Development of a clinical decision model for thyroid nodules. BMC Surg (2009) 1.21
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
Insulinoma: pathophysiology, localization and management. Future Oncol (2010) 1.21
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem (2004) 1.19
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology (2011) 1.18
Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion. J Biol Chem (2002) 1.18
Molecular pathology of the MEN1 gene. Ann N Y Acad Sci (2004) 1.16
Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide (2008) 1.14
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol (2005) 1.14
Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin. J Biol Chem (2003) 1.13
Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann Surg (2008) 1.13
Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep (2013) 1.12
Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res (2008) 1.12
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery (2008) 1.12
TSG-6 binds via its CUB_C domain to the cell-binding domain of fibronectin and increases fibronectin matrix assembly. Matrix Biol (2007) 1.11
Nitric oxide in wound-healing. Microsurgery (2005) 1.10
Heme oxygenase in Candida albicans is regulated by hemoglobin and is necessary for metabolism of exogenous heme and hemoglobin to alpha-biliverdin. J Biol Chem (2003) 1.09
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery (2013) 1.09
Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res (2002) 1.08
Malignant insulinoma: spectrum of unusual clinical features. Cancer (2005) 1.07
Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg (2002) 1.07
Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds. Nat Commun (2012) 1.06
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol (2005) 1.06
A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery (2005) 1.06
Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol (2011) 1.05
CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol (2008) 1.05
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg (2009) 1.05
Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach. J Nucl Med (2004) 1.05
Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res (2009) 1.05
Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res (2008) 1.05
Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells. Infect Immun (2011) 1.05
Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep (2013) 1.05
Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res (2008) 1.04
Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin. J Biol Chem (2005) 1.03
Antiangiogenic gene therapy of cancer: recent developments. J Transl Med (2004) 1.03
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res (2008) 1.03
Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med (2006) 1.02